News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2025 - 11 - 19

People's Daily | The 20th China Economic Forum Opens in Nansha!

On November 18, the 20th China Economic Forum, hosted by China Economic Weekly magazine under People's Daily, was successfully held at the Guangzhou Nansha International Convention Center.The China Economic Forum is a major economic forum event hosted by China Economic Weekly magazine under People's Daily. Since its inception in 2001, it has had a broad influence across government, business, and academic circles.It is reported that the theme of this year's forum is "Chinese Modernization and the Outlook for China's Economy in the 15th Five-Year Plan.&qu...

浏览次数：1

查看详情>>

发布时间: 2025 - 11 - 12

Andao Pharma Announces Completion of Over RMB 400 Million Series C Financing

Recently, Hangzhou Andao Pharmaceutical Co., Ltd. announced the completion of a Series C financing round exceeding RMB 400 million. This round was invested in by Grand Pharma (with Huadong Medicine as a major LP), Taiping Medical Health Fund, C&D Emerging Investment, Hangzhou Taikun, Zhejiang Province "4+1" Biopharmaceutical and High-End Medical Device Industry Fund, Guangzhou Industrial Investment, Guangzhou Development District, Science and Technology Financial Holding, and Hangzhou Talent Fund, among others, with follow-on investments from existing shareholders including Efung...

浏览次数：1

查看详情>>

发布时间: 2025 - 11 - 03

Betta Pharmaceuticals and Shengsi Bio Reach Strategic Cooperation

Recently, Betta Pharmaceuticals and Shengsi Bio reached a comprehensive strategic cooperation agreement. Betta Pharmaceuticals will provide support to Shengsi Bio across R&D, clinical development, manufacturing, registration, and sales & marketing to facilitate the R&D, industrialization, and commercialization of related products. Additionally, the two companies signed a commercial cooperation agreement granting Betta Pharmaceuticals exclusive distribution rights for FRSW117 (a long-acting recombinant coagulation factor VIII-Fc fusion protein for injection) in the Greater China reg...

浏览次数：1

查看详情>>

发布时间: 2025 - 10 - 28

First under Restarted STAR Market 5th Criteria! OriginBio Debuts with "Rice Hematopoietic" Tech

On October 28, OriginBio officially listed on the Science and Technology Innovation Board (STAR Market) with the stock code 688765 and an IPO price of 29.06 yuan per share. This marks the first listing of an unprofitable enterprise under the STAR Market's Fifth Set of Listing Criteria since China Securities Regulatory Commission Chairman Wu Qing announced the restart of this policy at the Lujiazui Forum on June 18. It not only signifies a substantial breakthrough in institutional innovation on the STAR Market but also rewrites the global biopharmaceutical landscape with a single strai...

浏览次数：1

查看详情>>